Amsterdam, the Netherlands, 30 June 2021 – Huvepharma B.V. (the “Company”) and together with its consolidated subsidiaries (the “Group”), a leading global livestock animal health company with strong positions in the veterinary and feed additives segments, today announced that the Group and its sole shareholder, Advance Properties OOD (the “Selling Shareholder”), have decided to stop the proposed IPO on Euronext Amsterdam.
This announcement is an advertisement for the purposes of the Prospectus Regulation EU 2017/1129 and underlying legislation, relating to the launch of the Offer (as defined below) by the Company and the proposed Admission (as defined below). This announcement does not constitute a prospectus. This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy Shares (as defined below) in any jurisdiction, including the United States, Canada, Australia or Japan. Further details about the Offer and the Admission is included in the Prospectus (as defined below). The Prospectus has today been approved by the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) (the “AFM”) and has been published today and made available at no cost on the Company’s corporate website (www.ir.huvepharma.com), subject to securities law restrictions in certain jurisdictions. An offer to acquire Shares pursuant to the Offer will be made, and any potential investor should make their investment, solely on the basis of information that is contained in the Prospectus. Potential investors should read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the Shares. The approval of the Prospectus by the AFM should not be understood as an endorsement of the quality of the Shares and the Company (as defined below).
Huvepharma Issues Voluntary Recall of Duramycin-10 Due to Stability Failure
Bulgaria headquartered Huvepharma, a global animal health company, will acquire certain assets from Zoetis, which include products and two owned and one leased US manufacturing sites. The assets associated with this deal involve an international portfolio of medicated feed additives, including Albac (excluding the USA market) and bio-Cox / Salinomax as well as InovocoxEM1, leading coccidiosis vaccine for broilers.
Zoetis, under pressure from investors to shape up, laid out a sweeping plan earlier this year to eliminate 10 plants and about 2,500 jobs as part of an effort to flush out operating costs and improve its margins. But the animal health leader did not specify at the time which plants would have to go. Now it has provided its first peek at its intentions and it is starting with a three-facility deal with a Bulgarian firm.